Vera Therapeutics announced that its ORIGIN Phase 3 trial of atacicept for IgA nephropathy met its primary endpoint, showing statistically significant and clinically meaningful reductions in ...

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, ...

The Gertrude von Meissner Foundation Research Prize rewards scientific projects in the field of prevention and treatment of disabilities and diseases in children and adolescents.

The APPLAUSE-IgAN results demonstrate that targeted, disease-modifying therapy can preserve long-term kidney function.

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

The ORIGIN Phase 3 trial met the primary endpoint with a statistically significant and clinically meaningful reduction in ...

Travere Therapeutics (TVTX) announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") today announced that it has reached an agreement with the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan regarding ...

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings ...

Novartis NVS recently announced positive final results from the late-stage, APPLAUSE-IgAN, study on Fabhalta (iptacopan) in ...

Objective To investigate second kidney biopsy as predictor of end-stage kidney disease (ESKD) in active lupus nephritis (LN). Methods Patients with biopsy-proven LN (International Society of ...